Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Bavencio (avelumab) Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0295

    Bavencio (avelumab) coverage and authorization

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0295 alerts

    Get alerted when Policy IC-0295 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Viva Health prior authorization, dosing limits, indications, renewal, and administration rules for intravenous avelumab (Bavencio) for oncology indications; applies to providers requesting coverage for members receiving avelumab.

    Policy Summary
    PayerViva Health
    PolicyBavencio (avelumab) coverage and authorization
    Policy CodePolicy IC-0295
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization—initial approvals valid 6 months (180 days) and may be renewed every 6 months; document dosing and diagnosis to support medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial PA length
    6 monthsrenewal interval
    800 mg q14dmax dosing
    10 mg/kgweight-based alt

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J9023
    HCPCS
    44087-3535-xxNDC

    Coverage Criteria for Bavencio (avelumab)

    Initial Therapy

    Covered when ALL of the following universal and indication-specific criteria are met:

    Universal criteria

    • Age: Member is at least 18 years of age, unless otherwise indicated (some indications permit >=12)>=18 or indication-specific

      chunk 5

    • Prior PD therapy: Member has not received previous therapy with a PD-1/PD-L1-directed therapy unless otherwise specifiedno prior PD-1/PD-L1

      chunk 6

    Merkel Cell Carcinoma (MCC): Member is at least 12 years of age; used as single-agent therapy for primary locally advanced, recurrent locally advanced, in-transit N+ regional, metastatic, or primary/recurrent regional disease when curative surgery and curative radiation therapy are not feasible; progression on neoadjuvant nivolumab permits useage >=12

    FDA and compendia indications

    Urothelial Carcinoma: Used as single-agent therapy for locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy, OR used as first-line maintenance treatment for locally advanced/metastatic disease in members who have not progressed on first-line platinum-containing chemotherapyplatinum progression or maintenance after non-progression

    See chunk 8 for platinum and maintenance details

    Renal Cell Carcinoma (RCC): Used in combination with axitinib as first-line therapy for advanced, relapsed, or stage IV disease with clear cell histology (when used as first-line for stage IV, disease must be M1 or unresectable T4, M0)combination with axitinib, first-line

    chunk 10

    Gestational Trophoblastic Neoplasia: Used as single-agent therapy for multiagent chemotherapy-resistant disease for PSTT or ETT with recurrent or progressive disease, OR for high-risk disease (prognostic score >=7 or FIGO stage IV)multiagent chemo-resistant or high-risk

    chunk 11

    Endometrial Carcinoma: Used as subsequent therapy for recurrent disease; not for locoregional recurrence in members with no prior radiation to site of recurrence or previous vaginal brachytherapy only, and not after surgical exploration for locoregional recurrence confined to vagina/paravaginal soft tissue; used as single-agent for MSI-H/dMMR tumors or in combination with axitinib for pMMR tumorsrecurrent disease and biomarker-directed

    chunk 12

    Extranodal NK/T-Cell Lymphomas: Used as single agent for relapsed or refractory disease following additional therapy with an alternate asparaginase-based combination chemotherapy regimen not previously used, when clinical trial participation is unavailablepost-asparaginase regimen failure

    chunk 13

    Thymic Carcinomas: Used in combination with axitinib for specified settings (unable to tolerate first-line combos, postoperative systemic therapy after R1/R2 resection, first-line for recurrent/advanced/metastatic disease, or subsequent therapy for unresectable/metastatic disease)combination with axitinib or specified post-op/subsequent use

    chunk 14

    Colon/Rectal/Small Bowel Adenocarcinoma: Member has MSI-H/dMMR disease OR POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) confirmed by an FDA-approved or CLIA-compliant test; used as single agent for locally unresectable, medically inoperable, advanced or metastatic diseasebiomarker-confirmed hypermutated status

    chunks 15-16

    Renewal Therapy

    Approval may be renewed when ALL of the following are met:

    Renewal criteria: Member continues to meet the universal and indication-specific criteria; disease response is demonstrated as stabilization or decrease in tumor size or spread; and there is absence of unacceptable toxicityclinical benefit and tolerability

    Examples of unacceptable toxicity include severe infusion reactions, severe immune-mediated adverse events, MACE, HSCT complications

    Covered Diagnoses

    Covered when the patient's diagnosis is listed in Appendix 1

    Appendix 1 diagnosis requirement: The claim must be associated with one of the ICD-10 diagnosis codes listed in Appendix 1 (see chunks 36-38 for the full code list)

    See full code list in Appendix 1

    Medicare / CMS

    Medicare Part B coverage considerations

    Medicare guidance: Medicare NCDs, LCDs, and LCAs may apply and must be followed where relevant; additional indications may be applied at the discretion of the health plan

    Medicare Part B Covered Diagnosis Codes listed as N/A in this excerpt

    For endometrial carcinoma, avelumab is authorized only as subsequent therapy for recurrent disease and must meet the indication-specific requirements. The policy explicitly states that avelumab will not be used for (1) locoregional recurrence in members who have had no prior radiation to the site of recurrence or who had only prior vaginal brachytherapy, or (2) therapy after surgical exploration for locoregional recurrence confined to the vagina or paravaginal soft tissue. When covered, avelumab may be used either as a single agent for MSI-H/dMMR tumors or in combination with axitinib for pMMR tumors.

    If a member’s tumor is re-biopsied and the pathology demonstrates a change in an actionable mutation (for example, an initial MSS biopsy that is subsequently MSI-H), re-initiation of PD-directed therapy is not automatic. Such requests to restart PD-1/PD-L1 therapy will be reviewed individually; eligibility to re-initiate therapy will be determined on a case-by-case basis based on the new biopsy findings and clinical context.

    Within the excerpted policy material, there are no specific Medicare Part B diagnosis codes provided. The document notes that Medicare Part B Covered Diagnosis Codes are listed as N/A in this excerpt and advises that applicable NCDs/LCDs/LCAs must be followed where relevant.

    Use of avelumab is restricted for members who have previously received a PD-1 or PD-L1 directed therapy. Unless an indication-specific criterion explicitly allows prior PD-1/PD-L1 exposure, the member must have no prior PD-1/PD-L1-directed therapy to meet the universal criteria for coverage.

    Coding, Dosing, and Identifiers

    Dosing/HCPCS unitHCPCS
    HCPCS unit: 80 billable units800 mg every 14 days (all indications)
    Covered HCPCS CodesHCPCSCovered
    J9023Injection, avelumab, 10 mg; 1 billable unit = 10 mg
    Product NDCNDC
    44087-3535-xxBavencio 200 mg/10 mL single-dose vial NDC
    Covered ICD-10 Codes (partial list) - group 1ICD-10Covered
    C17.0Malignant neoplasm of duodenum
    C17.1Malignant neoplasm of jejunum
    C17.2Malignant neoplasm of ileum
    Covered ICD-10 Codes (partial list) - group 2ICD-10Covered
    C64.2Malignant neoplasm of left kidney, except renal pelvis.
    C64.9Malignant neoplasm of unspecified kidney, except renal pelvis.
    C65.1Malignant neoplasm of right renal pelvis.
    C65.2Malignant neoplasm of left renal pelvis.
    C65.9Malignant neoplasm of unspecified renal pelvis.
    C66.1Malignant neoplasm of right ureter.
    C66.2Malignant neoplasm of left ureter.
    C66.9Malignant neoplasm of unspecified ureter.
    C67.0Malignant neoplasm of trigone of bladder.
    C67.1Malignant neoplasm of dome of bladder.
    1–10 of 23
    1/3
    Covered ICD-10 Codes (continued) - group 3ICD-10Covered
    C78.7Secondary malignant neoplasm of liver and intrahepatic bile duct.
    C7B.1Secondary Merkel cell carcinoma.
    C84.90Mature T/NK-cell lymphomas, unspecified, unspecified site.
    C84.91Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck.
    C84.92Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes.
    C84.93Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes.
    C84.94Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb.
    C84.95Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb.
    C84.96Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes.
    C84.97Mature T/NK-cell lymphomas, unspecified, spleen.
    1–10 of 34
    1/4
    Medicare Jurisdiction mappingsmixed
    Medicare Jurisdiction mappingsText lists MAC jurisdictions and contractors (e.g., Jurisdiction E(1) = CA, HI, NV, AS, GU, CNMI; contractor Noridian Healthcare Solutions, LLC).
    inv-16: Dosing frequency — 800 mg every 14 days
    Dosing frequencyAdminister 800 mg intravenously every 14 days until disease progression or unacceptable toxicity.
    Calculation noteDosing should be calculated using actual body weight and not flat dosing when applicable.
    Administration routeIntravenous (infusion).
    inv-17: Weight threshold for alternative dosing — ≤ 66 kg
    Weight thresholdUse weight ≤ 66 kg as threshold for alternative weight-based dosing (10 mg/kg).

    Provider Actions, Documentation, and Authorization Rules

    Prior Authorization

    Obtain prior authorization and adhere to dosing limit

    Prior authorization (PA) is required for Bavencio (avelumab). Initial approvals are valid for 6 months (180 days); renewals may be granted every 6 months thereafter. The policy limits dosing to a maximum of 80 billable units (800 mg) every 14 days for all indications.

    • Initial PA length: 6 months (180 days)
    • Renewal interval: every 6 months (180 days)
    • Dosing limit: 80 billable units (800 mg) every 14 days
    Prior Authorization

    Expect PA consideration due to drug cost

    The NQTL checklist identifies drug cost as a factor considered when applying prior authorization; providers should expect PA review may be used due to cost considerations.

    • NQTL checklist flags Cost of drug = Yes: Consider for PA

    Initial Dosing and Administration Criteria

    Initial Dosing

    Initial dosing and administration

    Dose and frequency: Administer 800 mg intravenously every 14 days until disease progression or unacceptable toxicity; dosing should be calculated using actual body weight where applicable and not rely solely on flat dosing examples800 mg q14d

    Max units: 80 billable units (800 mg) every 14 days

    Standard dose

    Dosing instruction for initiation/maintenance

    Avelumab dosing: Administer 800 mg intravenously every 14 days until disease progression or unacceptable toxicity; calculate dosing using actual body weight when applicable

    chunk 19

    Continuation and Renewal Criteria

    Continuation Therapy

    Continuation (renewal) is allowed when clinical benefit and tolerability continue.

    Continuation: Member shows disease stabilization or tumor reduction and absence of unacceptable toxicity; continues to meet universal and indication-specific criteriaclinical response and tolerability

    chunk 17

    Step Therapy and Prior Treatment Requirements

    RequirementDetailsCoverage status
    Prior platinum therapy (urothelial carcinoma)
    Required for single‑agent use when disease progressed during or following platinum‑containing chemotherapy; applies to locally advanced or metastatic urothelial carcinoma (includes bladder, upper GU tract, urethra, and/or prostate)
    Conditionally covered
    First‑line maintenance (urothelial carcinoma)
    Permitted as first‑line maintenance when member has not progressed on first‑line platinum‑containing chemotherapy for locally advanced or metastatic urothelial carcinoma
    Conditionally covered
    Review triggerEvaluation approachCoverage status
    Tumor re‑biopsy showing change in actionable mutation
    Re‑initiation of PD‑directed therapy after re‑biopsy demonstrating a changed actionable mutation (e.g., MSS → MSI‑H) will be evaluated on a case‑by‑case basis
    Case‑by‑case review

    Quantity Limits and Site of Care

    inv-41: avelumab (Bavencio) — 80 billable units (800 mg) quantity limit
    Quantity limit (HCPCS units)80 billable units (800 mg) every 14 days.
    Coverage scopeLimit applies across indications as the maximum units per dose and over time.
    Billing equivalence1 billable unit = 10 mg (per HCPCS J9023 description elsewhere); 80 units = 800 mg.
    Note

    Intravenous administration — infusion center setting

    Avelumab is administered intravenously; follow the dosing and administration guidance provided for infusion delivery.

    Background

    Avelumab (Bavencio) is a PD-L1 checkpoint inhibitor indicated across multiple oncologic settings and subject to indication-specific coverage rules. The policy requires members to meet universal criteria such as age and absence of prior PD-1/PD-L1 therapy, and then applies indication-specific requirements (for example, Merkel cell carcinoma age thresholds, urothelial carcinoma platinum-therapy or maintenance conditions, and biomarker-directed use in endometrial and MSI-H/dMMR or POLE/POLD1 ultra-hypermutated tumors). For Medicare beneficiaries, the policy excerpt does not list Part B diagnosis codes and reminds providers that applicable Medicare NCDs/LCDs/LCAs must be followed.

    Definitions and Clarifications

    inv-32: Biomarker confirmation — MSI-H/dMMR and POLE/POLD1 mutation testing requirements
    Required testsMSI-H/dMMR or POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) must be determined by an FDA-approved or CLIA-compliant test.
    Acceptable assay noteIf confirmed using an immunotherapy assay, reference FDA companion diagnostics guidance.
    Indication linkBiomarker confirmation required for colon, rectal, and small bowel adenocarcinoma indications in this policy.
    inv-33: Flat dose vs weight-based dose — 800 mg q14d vs 10 mg/kg alternative example
    Standard flat dose800 mg IV every 14 days (standard listed dose for all indications).
    Weight-based alternative10 mg/kg IV every 2 weeks (example: 600 mg if weight ≤ 66 kg).

    Appendices: Full Code Listings

    Appendix 1 - Covered ICD-10 Codes (part)ICD-10Covered
    C17.0Malignant neoplasm of duodenum
    C17.1Malignant neoplasm of jejunum
    C17.2Malignant neoplasm of ileum
    C17.3Meckel's diverticulum, malignant
    C17.8Malignant neoplasm of overlapping sites of small intestine
    C17.9Malignant neoplasm of small intestine, unspecified
    C18.0Malignant neoplasm of cecum
    C18.2Malignant neoplasm of ascending colon
    C18.3Malignant neoplasm of hepatic flexure
    C18.4Malignant neoplasm of transverse colon
    1–10 of 17
    1/2
    Appendix 1 - Covered ICD-10 Codes (continued)ICD-10Covered
    C4A.0Merkel cell carcinoma of lip
    C4A.10Merkel cell carcinoma of eyelid, including canthus
    C4A.111Merkel cell carcinoma of right upper eyelid, including canthus
    C4A.112Merkel cell carcinoma of right lower eyelid, including canthus
    C4A.121Merkel cell carcinoma of left upper eyelid, including canthus
    C4A.122Merkel cell carcinoma of left lower eyelid, including canthus
    C4A.20Merkel cell carcinoma of unspecified ear and external auricular canal
    C4A.21Merkel cell carcinoma of right ear and external auricular canal
    C4A.22Merkel cell carcinoma of left ear and external auricular canal
    C4A.30Merkel cell carcinoma of unspecified part of face
    1–10 of 19
    1/2
    Appendix 1 - Covered ICD-10 Codes (continued, part)ICD-10Covered
    C84.90Mature T/NK-cell lymphomas, unspecified, unspecified site.
    C84.91Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck.
    C84.92Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes.
    C84.93Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes.
    C84.94Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb.
    C84.95Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb.
    C84.96Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes.
    C84.97Mature T/NK-cell lymphomas, unspecified, spleen.
    C84.98Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites.
    C84.99Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites.
    1–10 of 12
    1/2
    Appendix 2 - Medicare Part B jurisdiction mappingsmixed
    Jurisdiction mappingsLists MAC jurisdictions and contractors (examples include Jurisdiction E(1) = CA, HI, NV, AS, GU, CNMI; contractor Noridian Healthcare Solutions, LLC).
    Policy Summary
    PayerViva Health
    PolicyBavencio (avelumab) coverage and authorization
    Policy CodePolicy IC-0295
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization—initial approvals valid 6 months (180 days) and may be renewed every 6 months; document dosing and diagnosis to support medical necessity.
    SourceLink
    On This Page
    Coverage Criteria for Bavencio (avelumab)Coding, Dosing, and IdentifiersProvider Actions, Documentation, and Authorization RulesInitial Dosing and Administration CriteriaContinuation and Renewal CriteriaStep Therapy and Prior Treatment RequirementsQuantity Limits and Site of CareBackgroundDefinitions and ClarificationsAppendices: Full Code Listings
    Example dose at thresholdIf weight ≤ 66 kg, use 600 mg IV every 2 weeks (10 mg/kg example).
    PurposeDefines when to apply weight-based dosing instead of standard flat dose.
    inv-18: Medicare Part B Covered Diagnosis Codes — N/A
    Medicare Part B covered diagnosis codesN/A (no specific Part B diagnosis codes provided in this excerpt).
    GuidanceProviders must follow applicable NCDs, LCDs, and LCAs where relevant for Medicare Part B coverage.
    ReferenceSee Appendix 2 and CMS Medicare Coverage Database for applicable determinations.
    Billing Rule

    Follow applicable Medicare NCD/LCD/LCA guidance for Part B claims

    When billing under Medicare Part B, providers must follow applicable Medicare guidance — National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) — where relevant; noncompliance may affect coverage.

    • Medicare Part B coverage is governed by Pub. 100-2, Chapter 15 §50 and applicable NCDs/LCDs/LCAs
    • Medicare Part B Covered Diagnosis Codes listed as N/A in this excerpt, but NCD/LCD/LCA requirements still apply
    Step Therapy

    Confirm no prior PD‑1/PD‑L1 therapy unless indication allows

    Use of Bavencio is restricted if the member previously received PD-1/PD-L1–directed therapy unless an indication-specific exception applies; verify prior PD‑1/PD‑L1 therapy status before requesting PA.

    • Universal criterion: Member has not received prior PD‑1/PD‑L1 therapy unless otherwise specified
    Note

    (No action specified)

    (No specific provider instruction provided in source for this inventory placeholder.)

    Note

    (No action specified)

    (No specific provider instruction provided in source for this inventory placeholder.)

    Documentation Required

    Submit FDA‑approved or CLIA‑compliant tumor biomarker results

    Document tumor biomarker results (MSI‑H/dMMR or POLE/POLD1 ultra‑hypermutated phenotype) from an FDA‑approved or CLIA‑compliant test; if using an immunotherapy companion assay, reference FDA companion diagnostic resources.

    • MSI‑H/dMMR or POLE/POLD1 ultrahypermutated (e.g., TMB >50 mut/Mb) must be determined by an FDA‑approved or CLIA‑compliant test
    • If confirmed using an immunotherapy assay, reference FDA companion diagnostics guidance
    Documentation Required

    Document weight and dose calculation method

    Calculate and document the dose using the patient’s actual body weight when applicable; state whether flat dosing (800 mg every 14 days) or weight‑based dosing (10 mg/kg, e.g., 600 mg if ≤66 kg) was used and provide the weight supporting the calculation.

    • Dosing should be calculated using actual body weight and not flat dosing where applicable
    • Standard flat dose: 800 mg IV every 14 days; Weight ≤66 kg: use 600 mg (10 mg/kg) IV every 2 weeks
    Documentation Required

    Include a supported Appendix 1 ICD‑10 diagnosis code

    Include an ICD‑10 diagnosis code from Appendix 1 with the PA submission and claim to support medical necessity; the Appendix 1 code list (chunks 36–38) contains the covered diagnosis codes to use.

    • Claims and PA submissions must be associated with a diagnosis code listed in Appendix 1 (see chunks 36–38 for the code list)
    Denial Risk

    Provide evidence of response and tolerability for renewal

    Renewal requests may be denied if the member does not demonstrate disease stabilization or tumor decrease, or if unacceptable toxicity from the drug is present; provide objective evidence of clinical benefit and tolerability with renewal requests.

    • Renewal requires continued meeting of criteria plus disease stabilization or decrease in tumor size/spread
    • Renewal denied if unacceptable toxicity (e.g., severe infusion reactions, severe immune‑mediated AEs, MACE, HSCT complications) is present
    Documentation Required

    Submit re‑biopsy and mutation change documentation for case‑by‑case review

    If a tumor re‑biopsy demonstrates a change in an actionable mutation (for example, MSS initially and MSI‑H on subsequent biopsy), re‑initiation of PD‑directed therapy may be considered but will be evaluated on a case‑by‑case basis and is not automatic; document biopsy and mutation change details for review.

    • Re‑initiation after re‑biopsy showing changed actionable mutation will be evaluated case‑by‑case
    • Provide pathology and molecular results from re‑biopsy when requesting reconsideration
    Denial Risk

    Ensure Medicare policy compliance for Part B billing

    Noncompliance with Medicare NCD/LCD/LCA requirements where applicable may result in denial of coverage for Part B claims; ensure Medicare guidance is followed for beneficiaries and claims under Part B.

    • Medicare NCDs/LCDs/LCAs may exist and must be followed where applicable
    • Lack of compliance with Medicare guidance could trigger denial

    Weight-based dosing

    Weight-based dosing alternative

    Weight-based dose: For members with weight ≤ 66 kg, use 600 mg (10 mg/kg) IV every 2 weeksweight ≤ 66 kg

    chunk 20

    Dose calculation guidanceDosing should be calculated using actual body weight and not solely by flat dosing when applicable.
    inv-34: NCD/LCD/LCA — definitions of Medicare coverage artifacts
    NCD (National Coverage Determination)A national Medicare policy that may define coverage rules for Part B drugs; applicable NCDs must be followed where relevant.
    LCD (Local Coverage Determination)Region-specific Medicare contractor determinations that can govern coverage for Part B drugs in a jurisdiction.
    LCA (Local Coverage Article)Supplementary local articles used for claims payment guidance or to clarify benefit eligibility under Part B.